Rapidly Progressive Glomerulonephritis: Classification, Pathogenetic Mechanisms, and Therapy

American Journal of Kidney Diseases

Volumn 11, Issue 6, 1988, Pages 449-464

  Couser, William G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

anti GBM nephritis; Glomerulonephritis; Goodpasture's syndrome; immune mechanisms of renal disease; plasmapheresis; pulse steroids; RPGN; therapy of RPGN; vasculitis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISONE;

CLASSIFICATION; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; HISTOLOGY; HUMAN; PLASMAPHERESIS; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW; ULTRASTRUCTURE; VASCULITIS;

EID: 0023900868     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(88)80079-9     Document Type: Article

References (195)

1. The role of corticosteroids in nephritic syndromes: The case for aggressive use
2. The significance of extracapillary proliferation: Clinicopathological review of 60 patients
3. Idiopathic crescentic glomerulonephritis
4. Idiopathic rapidly progressive glomerulonephritis
5. Primary glomerular disease
6. Natural history of Bright's disease
7. Glomerulonephritis induced in sheep by injections of heterologous glomerular basement membrane and Freund's complete adjuvant
8. The role of antiglomerular basement membrane antibody in the pathogenesis of human glomerulonephritis
9. Rapidly progressive (nonstreptococcal) glomerulonephritis
10. An immunopathologic study of rapidly progressive glomerulonephritis in the adult
11. Crescentic glomerulonephritis without immune deposits
12. Crescentic glomerulonephritis: Immune v nonimmune mechanisms
13. Circulating and deposited immune complexes in patients with glomerular disease
14. Renal response to immunological injury
15. Evolution of membranous nephropathy into anti-glomerular-basementmembrane glomerulonephritis
16. Progression from membranous glomerulopathy to antiglomerular basement membrane (GBM) antibody mediated crescentic nephritis
17. Evidence of both anti-GBM and immune complex mediated pathogenesis in the initial phase of Goodpasture's syndrome
18. Immunopathology of the end stage kidney
19. Vasculitis affecting the kidney: Presentation, histopathology and long-term outcome
20. Renal vasculitis (Nephrology Forum)
21. Idiopathic crescentic glomerulonephritis or systemic vasculitis?
22. A clinicopathologic comparison between antigranulocyte cytoplasmic autoantibody-positive idiopathic necrotizing and crescentic glomerulonephritis and arthritis-associated glomerulonephritis
23. Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis
24. Mechanisms of glomerular injury in immune-complex disease
25. In situ formation of immune complexes and the role of complement activation in glomerulonephritis
26. Immunopathogenesis of glomerular capillary wall injury in nephrotic states
27. Association between hydrocarbon exposure and glomerulonephritis
28. Hydrocarbon exposure in glomerulonephritis: Evidence from patients' occupations
29. Rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis during treatment with high-dosage D-penicillamine
30. Goodpasture's syndrome associated with influenza AZ virus infection
31. Acute glomerulonephritis with prolonged oliguria
32. Rapidly progressive (‘crescentic’) glomerulonephritis and monoclonal gammapathies
33. Rapidly progressive glomerulonephritis and monoclonal gammopathy
34. Crescentic glomerulonephritis and renal failure associated with malignant lymphoma
35. Crescentic glomerulonephritis associated with nonrenal malignancies
36. The influence of HLA-linked genes on the severity of anti-GBM antibody-mediated nephritis
37. Strong association between HLA-DRW2 and antibody-mediated Goodpasture's syndrome
38. HLA complex and susceptibility to glomerulonephritis
39. Association between rapidly progressive glomerulonephritis and the properdin factor BfF and different HLA-D region products
40. Renal disease in the elderly: Clinicopathologic analysis of renal disease in 115 elderly patients
41. Glomerulonephritis in the elderly
42. Experimental anti-alveolar basement membrane antibody-mediated pneumonitis
43. Binding of anti-basement membrane antibody to alveolar basement membrane after intratracheal gasoline installation in rabbits
44. Treatment and prognosis in antibasement membrane antibody-mediated nephritis
45. A mini-epidemic of Goodpasture's syndrome
46. Neoplasia and glomerular injury
47. The morphogenesis of glomerular crescents in rapidly progressive glomerulonephritis
48. Glomerular basement membrane discontinuities
49. Anti-GBM antibody-induced proteinuria in isolated perfused rat kidney
50. Direct anti-GBM antibody induced alterations in glomerular permselectivity
51. Experimental GN in the guinea pig
52. Experimental glomerulonephritis in the guinea pig
53. Guinea pig nephrotoxic nephritis
54. Complement-independent nephrotoxic nephritis in the guinea pig
55. Role of the terminal complement pathway in experimental membranous nephropathy in the rabbit
56. Role of the terminal complement pathway in the heterologous phase of antiglomerular basement membrane nephritis in the rabbit
57. Complement and the direct mediation of immune glomerular injury: A new perspective (Editorial Review)
58. Immunologic tissue injury mediated by neutrophilic leukocytes
59. Renal involvement in systemic lupus erythematosus: A study of 56 patients emphasizing histologic classification
60. Renal disease in essential mixed cryoglobulinemia
61. A role of polymorphonuclear leukocytes and complement in nephrotoxic nephritis
62. Potential role of platelet-activating factor in renal pathophysiology
63. Chemotaxis of monocytes and neutrophils to platelet-derived growth factor
64. The mediation of the localization of polymorphonuclear leukocytes in glomeruli during the autologous phase of nephrotoxic nephritis
65. Evidence for the role of oxygen radicals in acute nephrotoxic nephritis
66. Role of oxygen radicals in phorbol myristate acetate-induced glomerular injury
67. Glomerular injury and proteinuria in rats after intrarenal injection of cobra venom factor
68. A new mechanism for glomerular injury: The myeloperoxidase-hydrogenperoxide-halide system
69. Participation of the myeloperoxidase-(H202)-halide system in immune complex nephritis
70. Degradation of human glomerular basement membrane by stimulated neutrophils
71. The effect of oxidants on neutrophil-mediated degradation of glomerular basement membrane collagen
72. Oxidative autoactivation of latent collagenase by human neutrophils
73. Platelets mediate neutrophil-dependent glomerulonephritis induced by subendothelial immune complex deposits
74. A mononuclear cell component in experimental immunological glomerulonephritis
75. Macrophage-induced glomerular injury
76. T-lymphocyte participation in antigen-induced experimental glomerulonephritis
77. Cyclosporin A inhibits acute serum sickness in rabbits
78. Cellular composition of crescents in human rapidly progressive glomerulonephritis identified using monoclonal antibodies
79. Macrophage-induced glomerular fibrin deposition in experimental glomerulonephritis in the rabbit
80. The participation of macrophages, glomerular procoagulant activity, and Factor VIII in glomerular fibrin deposition
81. Quantitation and characterization of glomerular procoagulant activity in experimental glomerulonephritis
82. Cell culture approaches to the analysis of glomerular inflammation
83. Neutral proteinase activity produced in vitro by cells of the glomerular mesangium
84. Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells
85. The modulation of la antigen expression in rat glomeruli during the course of glomerulonephritis and aminonucleoside nephrosis
86. A cell mediated reaction against glomerular-bound immune complexes
87. A role of mononuclear phagocytes in immunologically induced glomerulonephritis
88. New avian model of experimental glomerulonephritis consistent with mediation by cellular immunity
89. Transfer of experimental autoimmune glomerulonephritis in chickens by sensitized cells
90. Differential effects of steroids on leukocyte-mediated glomerulonephritis in the rabbit
91. The macrophage in human rapidly progressive glomerulonephritis
92. Monocytes, proliferation and glomerulonephritis (Editorial)
93. Intraglomerular T cells and monocytes in nephritis: Study with monoclonal antibodies
94. In vitro evidence for cellular hypersensitivity to glomerular-basement-membrane antigens in human glomerulonephritis
95. Detection of humoral and cell-mediated immunity to kidney basement membranes in human renal diseases
96. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor
97. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1
98. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induced biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells
99. Monocytes in human glomerulonephritis
100. The origin of glomerular crescents in experimental nephrotoxic serum nephritis in the rabbit
101. Renal cell turnover studied by Y chromosome (Y body) staining of the transplanted human kidney
102. Histogenesis of glomerular crescents
103. Distribution of mononuclear phagocytes in glomerulonephritis with crescents
104. Immunopathogenesis of crescentic glomerulonephritis and lung purpura
105. The effect of defibrination on nephrotoxic serum nephritis in rabbits
106. Defibrination with ancrod in experimental chronic immune complex nephritis
107. Sequential studies of glomerular crescent formation in rats with antiglomerular basement membrane-induced glomerulonephritis and the role of coagulation factors
108. Procoagulant activity in glomeruli and urine of rabbits with nephrotoxic nephritis
109. Monocyte chemotaxis: Stimulation by specific exosite region in thrombin
110. Interleukin (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells
111. Induction of activation antigens on human glomerular endothelium by interleukin 1(IL-1 ), interferon gamma (IFN-g), and endotoxin (LPS)
112. Vascular endothelium: Nature's blood container
113. The composition of glomerulosclerosis
114. Analysis of risk factors for patient and renal survival in crescentic glomerulonephritis
115. The existence of a protracted course in crescentic glomerulonephritis
116. Clinical and morphological aspects of the management of crescentic anti-glomerular basement membrane antibody (anti-GBM) nephritis/Goodpasture's syndrome
117. Intravenous pulse methylprednisolone therapy of acute crescentic rapidly progressive glomerulonephritis
118. Plasmapheresis: Development and application in treatment of renal disorders
119. Overview of treatment of lupus nephropathy
120. Plasma exchange in Goodpasture's syndrome
121. Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis
122. Goodpasture's syndrome
123. Spontaneous recovery from rapidly progressive glomerulonephritis
124. Anti-glomerular basement membrane antibody-induced glomerulonephritis
125. Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis
126. Goodpasture's syndrome with normal renal function
127. Goodpasture's syndrome with normal renal function
128. Goodpasture's syndrome: Two cases with contrasting early course and management
129. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis
130. Plasmapheresis and immunosuppressive agents in antibasement membrane antibody-induced Goodpasture's syndrome
131. Treatment of Goodpasture's sydrome with plasmapheresis
132. Plasma exchange in nephritis
133. Therapy of anti-glomerular basement membrane antibody disease: Analysis of prognostic significance of clinical, pathologic and treatment factors
134. Plasmapheresis in SLE
135. Plasmaexchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis
136. Clinical course of severe lupus nephritis during the controlled clinical trial of plasmapheresis therapy
137. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4
138. Plasmapheresis in rapidly progressive glomerulonephritis
139. Use of combined plasmapheresis and immunosuppression in the treatment of Goodpasture's syndrome
140. Treatment of Goodpasture syndrome with cyclophosphamide, prednisone and plasma exchange transfusions
141. Effect of early plasmapheresis and immunosuppressive therapy on natural history of anti-glomerular basement membrane glomerulonephritis
142. Plasmapheresis in glomerulonephritis
143. Treatment of Goodpasture's disease by plasma exchange and immunosuppression
144. Failure of plasma exchange and immunosuppression to improve renal function in Goodpasture's syndrome
145. Goodpasture's syndrome-7 years' experience of two Dublin renal units
146. Goodpasture's syndrome: Treatment with plasmapheresis, immunosuppression, and anticoagulation
147. Treatment of Goodpasture's syndrome with plasma exchange and immunosuppression
148. Treatment of Goodpasture's syndrome with immunosuppression and plasmapheresis
149. Goodpasture's syndrome in a child: Natural history and effect of treatment
150. Immunosuppression and the additive effect of plasma exchange in treatment of rapidly progressive glomerulonephritis
151. Recovery from rapidly progressive glomerulonephritis
152. Goodpasture's syndrome treated with plasmapheresis
153. Goodpasture syndrome treated with immunosuppression and plasma exchange
154. Goodpasture's syndrome-Effects of plasmapheresis
155. Antiglomerular basement membrane antibody-mediated glomerulonephritis and Goodpasture's syndrome
156. Serious pulmonary hemorrhage, glomerulonephritis and massive steroid therapy
157. Plasma exchange for glomerular disease
158. Acute glomerulonephritis in middle-aged and elderly patients
159. The clinical spectrum of renal insufficiency during acute glomerulonephritis in the adult
160. Extracapillary proliferative glomerulonephritis so-called malignant glomerulonephritis
161. The longterm course of poststreptococcal glomerulonephritis
162. Combined immunosuppression and anti-coagulation in rapidly progressive glomerulonephritis
163. Rapidly progressive glomerulonephritis; a clinical and pathologic study
164. Combined anticoagulant and immunosuppressive treatment in rapidly progressive glomerulonephritis (RPGN)
165. Is rapidly progressive glomerulonephritis treatable?
166. Extracapillary proliferative glomerulonephritis in children
167. Acute poststreptococcal glomerulonephritis in adults: A long-term study
168. Poststreptococcal crescentic glomerulonephritis in children: Comparison of quintuple therapy v supportive care
169. The progression of acute proliferative post-streptococcal glomeru-lonephritis to severe epithelial crescent formation
170. Clinical and pathologic features of polyarteritis nodosa and its renal-limited variant: Primary crescentic and necrotizing glomerulonephritis
171. Pulse methylprednisolone therapy in the treatment of severe glomerulonephritis
172. Beneficial effects of methylprednisolone `pulse' therapy in diffuse prolif erative lupus nephritis
173. The treatment of lupus nephritis by methylprednisolone pulse therapy
174. High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus
175. Intractable hiccups associated with high-dose intravenous methylprednisolone therapy
176. Pulse methylprednisolone in rheumatoid arthritis: A double-blind cross-over trial
177. High-dose corticosteroids
178. Megadose methylprednisolone v plasmapheresis in treatment of rapidly progressive glomerulonephritis
179. Pulse methylprednisolone therapy in idiopathic, rapidly progressive glomerulonephritis
180. Pulse methylprednisolone therapy of acute crescentic and proliferative rapidly progressive glomerulonephritis
181. Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation
182. Effect of methylprednisolone on progressive Masugi nephritis in the rabbit
183. Efficacy of methylprednisolone pulses in the treatment of experimental glomerulonephritis
184. Plasma exchange in the treatment of glomerulonephritis
185. Plasma exchange and immunosuppressive drugs in the management of severe glomerulonephritis
186. Plasmapheresis in fulminating crescentic nephritis
187. Plasma exchange in immune complex glomerulonephritis: Clinical and immunological correlations
188. Plasmapheresis treatment of idiopathic rapidly progressive glomerulonephritis
189. Clinical trial of plasma exchange with a membrane filter in treatment of crescentic glomerulonephritis
190. Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis
191. Natural history and treatment of primary proliferative glomerulonephritis: A review